Top entities: Sun Pharma, India.

What category does this event fall under?

Regulatory — classified as product recall.

What is the sentiment of coverage?

Aggregate sentiment score: -20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Aug 02, 2026. Coverage continues to evolve.

Regulatory product recall

Sun Pharma recalls eye drops in India

Q: When did this event occur?

First reported Aug 01, 2026; last updated Aug 02, 2026.

Q: What is the market impact?

General. The recall may negatively impact Sun Pharma's sales in India and raise concerns about manufacturing quality, potentially affecting its stock price.

Analysis based on 13 articles · First reported Aug 01, 2026 · Last updated Aug 02, 2026

Sentiment

-20

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The recall may negatively impact Sun Pharma's sales in India and raise concerns about manufacturing quality, potentially affecting its stock price. However, the company's proactive response and focus on patient safety may mitigate long-term reputational damage.

Pharmaceuticals

Event Summary

Sun Pharma Distributors Ltd, a subsidiary of Sun Pharma, issued a confidential letter on July 17, 2026, to distributors in India announcing the precautionary withdrawal of multiple eye drop products, including Depopred, Brinolar, Brinzotim, Lotepred, Nepalact, and Toba-F. The company instructed distributors to immediately cease billing and return all existing stocks, citing patient safety as the highest priority. The withdrawal follows a contamination scare, though the exact reason was not specified. A Sun Pharma spokesperson stated that the company is working to restore availability of these products. Medical experts warned that interruption of treatment for conditions like glaucoma and post-surgery recovery could have significant consequences, urging patients to consult ophthalmologists for alternatives.

Key Actions

100 Sun Pharma withdrew eye drops

Entities Involved

stock

Sun Pharma

Sun Pharma initiated the precautionary withdrawal of multiple eye drop products in India due to a contamination scare, instructing distributors to stop billing and return stocks. This action may lead to short-term revenue loss and reputational risk, but the company's emphasis on patient safety could help maintain trust.

Importance 100.0 Sentiment -30.0

cnt

India

India is the market where the recall occurred, affecting patients and distributors. The event highlights regulatory and safety concerns in the Indian pharmaceutical market, potentially prompting closer scrutiny of manufacturing practices.

Importance 50.0 Sentiment -10.0

Relationships

Sun Pharma related ↔ India

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard